Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

144.81 +1.40 (+0.98%)
Streaming Delayed Price Updated: 11:44 AM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,449,397
Open 143.41
Bid (Size) 144.78 (1)
Ask (Size) 144.80 (1)
Prev. Close 143.41
Today's Range 143.27 - 145.49
52wk Range 130.96 - 168.11
Shares Outstanding N/A
Dividend Yield 4.09%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $ 
Via Benzinga
AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains
AbbVie's $10.1 billion acquisition of ImmunoGen, with its promising ovarian cancer drug, Elahere, signals a strategic move in the competitive cancer drug market. Investors anticipate market reactions,... 
Via Talk Markets

Performance

YTD
-10.82%
-10.82%
1 Month
+2.40%
+2.40%
3 Month
-0.88%
-0.88%
6 Month
+5.81%
+5.81%
1 Year
-11.67%
-11.67%

More News

Read More
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
5 S&P 500 Stocks That Pay a Generous Dividend
Via The Motley Fool
Topics Stocks
Exposures US Equities
Analyst Ratings for AbbVie
Via Benzinga
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
These biotechs targeting multiple neurodegenerative diseases
Via MarketBeat
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Via Talk Markets
Why Abbvie Stock Popped Today
Via The Motley Fool
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
Via InvestorPlace
AbbVie Should Consider a Dividend Cut -- Here's Why
Via The Motley Fool
Medtronic Stock: Bull vs. Bear
Via The Motley Fool
How Is The Market Feeling About AbbVie?
Via Benzinga
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
Via Investor's Business Daily
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
Via InvestorPlace
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
Via Benzinga
These are the top sectors for blue chip growth in 2024
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
3 Rising Stars: Invest Now in Tomorrow’s Trillion-Dollar Companies
Via InvestorPlace
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Could AbbVie Stock Help You Become a Millionaire?
Via The Motley Fool
3 "Boring" Stocks That Could Make You Rich
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.